111 (NASDAQ:YI) Earns “Sell (D-)” Rating from Weiss Ratings

111 (NASDAQ:YI)‘s stock had its “sell (d-)” rating reissued by equities researchers at Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

111 Stock Up 3.5 %

YI stock opened at $10.49 on Friday. The firm has a market capitalization of $89.71 million, a PE ratio of -2.62 and a beta of 0.46. 111 has a twelve month low of $4.15 and a twelve month high of $14.10. The stock’s 50 day moving average is $7.22 and its 200-day moving average is $7.33.

111 (NASDAQ:YI) last announced its earnings results on Thursday, March 20th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $527.14 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its holdings in shares of 111 by 43,619.9% in the 4th quarter. JPMorgan Chase & Co. now owns 306,039 shares of the company’s stock worth $191,000 after buying an additional 305,339 shares during the last quarter. Napean Trading & Investment Co Singapore PTE Ltd bought a new stake in 111 in the fourth quarter worth about $245,000. Finally, FIL Ltd bought a new stake in 111 in the fourth quarter worth about $450,000. Hedge funds and other institutional investors own 21.32% of the company’s stock.

About 111

111, Inc engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies.